08:00 , Jan 10, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
08:00 , Jan 6, 2005 |  BC Extra  |  Financial News

Simmonds joins Nomura

Julie Simmonds joined Nomura as a research analyst on the biotechnology and pharmaceutical equity research team. Simmonds will focus on medical technology and healthcare. Previously she was with Evolution Beeson Gregory, where she covered the...
07:00 , May 5, 2003 |  BC Week In Review  |  Company News

Protherics, Enact Pharma plc deal

PTI will acquire Enact for about £7.9 million ($12.6 million). PTI will pay £17.05 ($27.10) of PTI convertible loan notes and other considerations for every 100 Enact shares. PTI had £6.2 million ($9.8 million) in...
07:00 , May 2, 2003 |  BC Extra  |  Company News

Protherics to acquire Enact

Immunotherapeutic company Protherics (LSE:PTI) will acquire Enact Pharma (OFEX:Enact) for about L7.9 million ($12.6 million). PTI will pay L17.05 ($27.10) of PTI convertible loan notes and other considerations for every 100 Enact shares. PTI had...
08:00 , Jan 13, 2003 |  BioCentury  |  Finance

Biotech coverage in Europe

Biotech coverage in Europe Bank Bankers Analysts ABN-AMRO Tommy Erdei; Ton Gardeniers; Vijay Karwal; Claus May; Dirk Siewert Adrian Howd Baden-Wurttembergische Bank None dedicated Christine Feller; Peter Herrmanns; Michael Leineweber; Oliver Schwarz Banc of America...
07:00 , May 28, 2002 |  BioCentury  |  Finance

Ebb & Flow

Biogen's positive FDA panel for its Amevive psoriasis compound could loosen the first screw in the bolted biotech funding window for follow-ons, but is likely to stop short of throwing the window open. The IPO...
08:00 , Mar 11, 2002 |  BioCentury  |  Finance

Ebb & Flow

The good news is that biotech almost kept pace with NASDAQ last week; the bad news is it has a ways to go to catch up with the composite on a year-to-date basis. The NASDAQ...
08:00 , Mar 7, 2002 |  BC Extra  |  Financial News

Provalis raises L10.8 million

Provalis (LSE:PRO) raised L10.8 million ($15.5 million) in a placing and open offer of 96 million shares at 11.25p. Rothschild and Beeson Gregory were the underwriters. PRO directors will take up some 311, 000 shares...
08:00 , Mar 4, 2002 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Antisoma plc (LSE:ASM; NASD-EU:ASOM), London, U.K. Business: Cancer Beeson Gregory analyst Julie Simmonds raised her rating to "hold." She said the company's £23.7 million ($33.9 million) financing earlier this month removes the downward pressure on...
08:00 , Dec 10, 2001 |  BioCentury  |  Finance

Stocking stuffers

Pre-holiday fundraisers look to be having a jolly time, as debt and equity deals topped $1.6 billion in the first week of December. And in keeping with the season, some companies - much like most...